Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
8/10/18 2450: Post-TED Modify Modified (added text in red and deleted text is struck-out) the instructions for reporting the “date assessed” for questions 80, 83, 87, 90, 96, and 96:
If the best response is “not in complete remission,” report the date of the most recent testing performed during the reporting period and prior to relapse or progression treatment for relapsed, progressive, or persistent disease, if applicable. If no treatment for relapsed, progressive, or persistent disease was given, report the date of the most recent disease-specific testing performed within approximately 30 days of the follow-up date.
8/10/18 2014: MDS/MPN Pre-HCT Added Added an instructional blue box for question 123:
Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. The CIBMTR forms capture disease subtype using the WHO classification of myeloid neoplasms and acute leukemia. Secondary myelofibrosis is not included as a separate category per the WHO classification. Therefore, when reporting the disease subtype at the time of transplant for recipients with secondary myelofibrosis, report “Primary Myelofibrosis (PMF)” to accurately capture these cases on the CIBMTR Forms.
8/10/18 2402: Disease Classification Modify Modified (red text was added, struck out text was deleted) the instructional blue box for question 212:
Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. The CIBMTR forms capture disease subtype using the WHO classification of myeloid neoplasms and acute leukemia. Secondary myelofibrosis is not included as a separate category per the WHO classification. Therefore, when reporting the disease subtype at the time of transplant for recipients with secondary myelofibrosis, report “Primary Myelofibrosis (PMF)” to accurately capture these cases on the CIBMTR Forms. Myelofibrosis that develops in patients with essential thrombocythemia (ET) or polycythemia vera (PV) is considered secondary myelofibrosis. However, effective immediately, cases of post-essential thrombocythemia myelofibrosis (post-ET MF) or post-polycythemia vera myelofibrosis (post-PV MF) will now be reported as “Primary Myelofibrosis (PMF)” at the time of HCT. In order to capture accurate data, the secondary MF cases need to be lumped in with the PMF cases, since treatment for post-ET MF and post-PV MF is the same as PMF.
8/10/18 2010: AML Pre-Infusion Add Added the following instruction for questions 72 – 74:
If a differential was performed and there were no blasts present in the peripheral blood, the laboratory report may not display a column for blasts. In this case, it can be assumed that no blasts were present and “0” can be reported on the form.
8/10/18 2450: Post-TED Remove Removed the following instruction from questions 157 and 231:
Reporting the administration of a cellular therapy / donor cellular infusion in question 231 will generate additional cellular therapy forms which are used to capture important details regarding the infusion(s).
8/10/18 2018: LYM Pre-Infusion Add Added instruction for question 217:
If the recipient had palpable disease on a physical exam, those results can be reported in the CT (radiographic) criteria.
8/9/18 2402: Disease Classification Add Added instruction for question 281-282: If the PET scan result is only documented as an ‘X’, report this as “Unknown” for question 281.
7/25/18 2100: Post-HCT Follow-Up Data Modify Version 4 of the 2100: Post-HCT Follow-Up Data Form (Form 2100) (formerly 100 Day Post-HSCT Data Form) section of the Forms Instructions Manual released. Version 4 corresponds to revision 5 of the Form 2100.
7/25/18 2540: Tepadina Supplemental Data Collection Add Version 1 of the 2540: Tepadina Supplemental Data Collection section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2540.

Feedback

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.

Post your comment on this topic.

Please do not use this for support questions.
For customer support, please contact us here.

Post Comment